Ikeguchi Masahide, Miyatani Kozo, Takaya Seigo, Matsunaga Tomoyuki, Fukumoto Youji, Osaki Tomohiro, Saito Hiroaki, Wakatsuki Toshiro
Department of Surgery, Division of Surgical Oncology, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago, 683-8504 Japan.
Indian J Surg Oncol. 2016 Mar;7(1):32-6. doi: 10.1007/s13193-015-0428-6. Epub 2015 Jul 1.
Optimal treatment of patients with gastric cancer with synchronous distant metastases is palliative chemotherapy. However, occasionally gastrectomy should be selected due to control bleeding from tumors, perforation, or obstruction. The aim of this study is to evaluate the survival benefits of non-curative gastrectomy for patients with synchronous distant metastasis. Total 78 gastric cancer patients with synchronous distant metastasis treated in our hospital between 2003 and 2012 were enrolled in this study. Of these, 74 patients (95 %) received S1 based chemotherapy. During the treatment, 37 patients (47.4 %) underwent palliative gastrectomy because of bleeding from tumors (n = 15), tumor perforation (n = 6), and obstruction (n = 16). Survival benefits were compared in resected and non-resected patients, retrospectively. The two groups were clinicopathologically similar. Palliative gastrectomy was performed safely (morbidity: 10.8 % and mortality: 0) in resection group. However, resection showed survival benefits only in 13 patients (16.7 %) with single metastasis and without peritoneal metastasis. Their 2-year survival rate was 40 % and their median survival was 19 months. Non-curative gastrectomy with precise surgical techniques followed careful postoperative nutrition management may improve survival only for patients with a single metastatic site, except for peritoneal dissemination.
对于伴有同步远处转移的胃癌患者,最佳治疗方法是姑息化疗。然而,偶尔因控制肿瘤出血、穿孔或梗阻而应选择胃切除术。本研究的目的是评估非根治性胃切除术对伴有同步远处转移患者的生存获益。2003年至2012年期间在我院接受治疗的78例伴有同步远处转移的胃癌患者纳入本研究。其中,74例患者(95%)接受了以S1为基础的化疗。在治疗过程中,37例患者(47.4%)因肿瘤出血(n = 15)、肿瘤穿孔(n = 6)和梗阻(n = 16)接受了姑息性胃切除术。回顾性比较了切除组和未切除组患者的生存获益。两组在临床病理特征上相似。切除组安全地进行了姑息性胃切除术(发病率:10.8%,死亡率:0)。然而,仅13例(16.7%)单发转移且无腹膜转移的患者切除术后显示出生存获益。他们的2年生存率为40%,中位生存期为19个月。采用精确手术技术并在术后进行仔细营养管理的非根治性胃切除术可能仅对单发转移部位(除腹膜播散外)的患者生存有改善作用。